Upcoming Deadline Alert:Brower Piven Encourages Shareholders
Who Have Losses in Excess of $100,000 from Investment in Zafgen, Inc. to
Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action
Lawsuit

December 14, 2015 05:46 PM Eastern Standard Time

STEVENSON, Md.--(BUSINESS WIRE)--The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been commenced in
the United States District Court for the District of Massachusetts on
behalf of purchasers of Zafgen, Inc. (NasdaqGS:ZFGN) (“Zafgen” or the
“Company”) common stock during the period between January 12, 2015 and
October 16, 2015, inclusive (the “Class Period”). Investors who wish to
become proactively involved in the litigation have until December 21,
2015 to seek appointment as lead plaintiff.

If you have suffered a loss from investment in Zafgen common stock
purchased on or after January 12, 2015 and held through the revelation
of negative information during and/or at the end of the Class Period, as
described below, and would like to learn more about this lawsuit and
your ability to participate as a lead plaintiff, without cost or
obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven either
by email at hoffman@browerpiven.com
or by telephone at (410) 415-6616. No class has yet been certified in
the above action. Members of the Class will be represented by the lead
plaintiff and counsel chosen by the lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must
apply to be appointed lead plaintiff and be selected by the Court. The
lead plaintiff will direct the litigation and participate in important
decisions including whether to accept a settlement for the Class in the
action. The lead plaintiff will be selected from among applicants
claiming the largest loss from investment in Company common stock during
the Class Period. Brower Pivenalso encourages anyone with
information regarding the Company’s conduct during the period in
question to contact the firm, including whistleblowers, former
employees, shareholders and others.

The complaint accuses the defendants of violations of the Securities
Exchange Act of 1934 by virtue of the defendants’ failure to disclose
during the Class Period that there were more thrombotic adverse events
related to beloranib during clinical studies than had been disclosed at
the beginning of the Class Period.

According to the complaint, following rumors that a patient had died in
an ongoing Phase 3 clinical trial of beloranib, following the Food and
Drug Administration informing the Company on October 15, 2015 that
beloranib has been placed on partial clinical hold, and following the
Company’s October 16, 2015 disclosure that the patient who died was
receiving beloranib, that there had been four thrombotic adverse events
in prior clinical studies of beloranib (two more than previously
reported) as well as two additional, previously undisclosed thrombotic
events in ongoing studies, for a total of six thrombotic events out of
400 patients receiving beloranib compared to zero thrombotic events in
the approximately 150 patients treated with a placebo, the value of
Zafgen shares declined substantially.

Attorneys at Brower Piven have extensive experience in litigating
securities and other class action cases and have been advocating for the
rights of shareholders since the 1980s. If you choose to retain counsel,
you may retain Brower Piven without financial obligation or cost to you,
or you may retain other counsel of your choice. You need take no action
at this time to be a member of the class.